By Aidan Finley , Consultant, Health Advances We are all well aware that oncology is rapidly undergoing significant changes. Encouraged...

By Jonathon Fendelman, Senior Practice Executive, Campbell Alliance The Celgene/Quanticel tie-up announced November 4, typifies a trend we’l...

By Richard Gliklich , MD, President and CEO, Outcome We all know, broadly speaking, the mission of comparative effectiveness research (CER)...

Guest post by Dr. David Shaywitz As the biopharmaceutical industry looks to revitalize itself through innovation , a lot of companies have s...

Angus Russell is CEO of Shire PLC . Shire is a global specialty biopharmaceutical company with 4300 employees in 28 countries. He will be th...

Ian Spatz, the former VP-global health policy at Merck, is a contributing editor to The RPM Report . Ian is the founder of the Rock Creek Po...

Steve Dickman is the CEO of CBT Advisors . He blogs about biotech, VC and personalized medicine at Boston Biotech Watch . Interested in gues...

There is always a self-congratulatory flavor to BIO’s annual meeting. Which is as it should be: it’s the lobbying group’s best venue for jus...

Michael Gilman is the CEO of Stromedix , a Cambridge, MA biotech developing novel drugs to treat fibrotic organ failure. You can follow him ...

For at least a decade, biotechs have been perceived by many observers as the likely evolutionary winners in the race for survival and prospe...

We here at The IN VIVO Blog probably get a little bit too caught up in our own blathering. As a tonic, we'll be inviting some outsider...

"You really like who?" We promise this is the last DOTY post for at least eleven months but no awards ceremony would be complete ...